Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Passes $91 Million Boost For FDA, And Releases Sequestered 2013 User Fees

This article was originally published in The Gray Sheet

Executive Summary

A 2014 omnibus appropriations bill passed by the House Jan. 15 and the Senate a day later would give FDA $2.55 billion in discretionary funding, a $91 million increase. In news applauded by the device industry, the bill would also make available $85 million in previously sequestered FDA user fees. President Obama was expected to quickly sign the bill before a Jan. 18 midnight deadline to prevent a government shutdown.

You may also be interested in...



AdvaMed Floats Legislation To Allow User-Fee Submissions During Shutdowns

As the partial US government shutdown enters its second month, the backlog of device pre-market applications is building. AdvaMed is proposing language that would allow FDA to accept and review new user-fee-funded submissions during government shutdowns.

FDA Budget, Physician Payments On Tap For Congress In The New Year

Congress is on a tight schedule to approve federal appropriations bills for FDA and other agencies. It may also take up comprehensive physician payment reform bills that passed out of committees late in 2013; legislation that could have important implications for the device space. Also to look out for: a changing of the guard in the powerful Senate Finance Committee.

CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts

Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.

Topics

Related Companies

UsernamePublicRestriction

Register

MT033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel